Invesque Inc. Completes Previously Announced Sale of 20 Seniors Housing Assets and its Ownership Interests in Commonwealth Senior Living
The 20-asset portfolio, as well as Invesque's ownership interests in Commonwealth, were sold and proceeds from the Transaction were used to repay all property level debt associated with the assets, extinguish all unpaid and accrued preferred equity associated with the portfolio, and to pay other transaction-related costs.
Upon completion of the Transaction, Commonwealth has ceased to manage any Invesque-owned properties. The Company's portfolio currently consists of 32 assets, 12 of which remain under definitive contract to be sold, subject to satisfaction or waiver of due diligence conditions in favour of the purchasers and other customary closing conditions as previously disclosed.
"The Commonwealth platform has been a large part of Invesque's story over the last five and a half years, and we wish the Commonwealth team nothing but the best in the future," stated Adlai Chester, Chief Executive Officer of Invesque. "We have determined that it is in the Company's best interest to exit the Commonwealth business and substantially reduce the leverage of the broader Company."
About Invesque
Invesque is a North American health care real estate company with an investment thesis focused on the premise that an aging demographic in North America will continue to utilize health care services in growing proportion to the overall economy. Invesque currently capitalizes on this opportunity by investing in a portfolio of income-generating, predominantly private pay seniors housing communities. Invesque's portfolio includes investments primarily in independent living, assisted living, and memory care, which are operated under long-term leases and joint venture arrangements with industry-leading operating partners. Invesque's portfolio also includes investments in owner-occupied seniors housing properties in which Invesque owns the real estate, and the licensed operations.
Forward-Looking Information
This press release contains certain forward-looking information and/or statements ("forward-looking statements"), that reflect and are provided for the purpose of presenting information about management's current expectations and plans relating to the future, including, without limitation, statements regarding the expected closing of the sale of certain assets under definitive agreements and the current composition of the Company's portfolio. Forward-looking information is typically identified by terms such as "anticipate," "believe," "continue," "expect," "expectations," "forecast," "may," "plan," "pro forma," "project," "should," "will," and other similar expressions that do not relate solely to historical matters and suggest future outcomes or events. Readers should not place undue reliance on forward-looking statements and are cautioned that forward-looking statements may not be appropriate for other purposes. Forward-looking information is generally based on a number of assumptions, opinions, and estimates, including, but not limited to, that the conditions to closing in respect of the sale of certain assets under definitive agreements will be satisfied or waived and that such transactions will close within the expected timeline. While these assumptions, opinions, and estimates are considered by the Company to be appropriate and reasonable in the circumstances as of the date of this press release and given the time period for such projections and targets, they are subject to a number of known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the conditions to closing in respect of one or more of the sale of certain assets under definitive agreements will not be satisfied or waived and that such transactions will not close at all or within the expected timeline, as well as the risks described in the Company's current annual information form and management's discussion and analysis, available on the Company's profile on SEDAR+ at www.sedarplus.ca., which risks may be dependent on market factors and not entirely within the Company's control. These forward-looking statements reflect current expectations of the Company as of the date of this press release and speak only as of the date of this press release. There can be no assurance that forward-looking statements will prove to be accurate as actual outcomes and results may differ materially from those expressed in these forward-looking statements. Readers are cautioned not to place undue reliance on any such forward-looking statements, which are given as of the date hereof, and not to use such forward-looking statements for anything other than the intended purpose. Further, except as expressly required by applicable law, the Company assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward- looking statements contained in this press release are expressly qualified by this cautionary statement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Market Online
27 minutes ago
- The Market Online
MediPharm lays out the implications for possible new U.S. cannabis rescheduling
MediPharm Labs states it is positioned for potential U.S. cannabis rescheduling, having completed FDA site registration and filed a Drug Master File for CBD API Rescheduling cannabis to Schedule III would enable expanded medical research and access programs in the U.S., similar to those in Canada, Australia, and Germany The company will release its Q2 2025 financial results before markets open on Thursday, August 14, 2025, continuing its commitment to transparency and growth MediPharm Labs stock (TSX:LABS) last traded at $0.07 MediPharm Labs (TSX:LABS) shared its insights into its U.S. FDA site registration and strategic readiness in light of the potential federal rescheduling of cannabis in the United States. This content has been prepared as part of a partnership with MediPharm Labs Corp. and is intended for informational purposes only. Recent communications from the U.S. federal government and widespread media coverage suggest that the administration is actively reviewing the reclassification of cannabis from a Schedule I to a Schedule III controlled substance. This shift would mark a significant milestone in federal cannabis policy, recognizing its medical benefits and unlocking new pathways for research and patient access. Implications of rescheduling cannabis If cannabis is reclassified as a Schedule III drug: It would formally acknowledge its medical utility at the federal level Researchers in the U.S. would gain broader access to cannabis products for clinical trials, overcoming the restrictive barriers currently imposed by Schedule I classification The move could pave the way for expanded medical cannabis programs similar to those in Canada, Australia, and Germany Cannabis businesses would benefit from tax relief under Section 280E, which currently penalizes Schedule I and II substance handlers MediPharm's unique positioning MediPharm Labs stands out as one of the few companies globally—and the only publicly listed cannabis-focused firm in North America—with a comprehensive suite of regulatory approvals and infrastructure to capitalize on this potential shift: The company has successfully completed the process of foreign drug manufacturing site registration with the U.S. FDA, including a week-long inspection that granted it the authority to produce, label, test, and release pharmaceutical-grade cannabis products MediPharm has filed a Drug Master File with the FDA for its CBD active pharmaceutical ingredient (API), an important step for enabling late-stage clinical trials and finished dose product development It has already shipped cannabis API and products to the U.S. for research purposes, including a National Institutes of Health-funded clinical trial—an achievement made possible through FDA registration and DEA-issued import permits With these credentials, MediPharm sees itself in a stable position to support the anticipated surge in U.S.-based cannabis research and potential new medical access programs. The company's purpose-built, FDA-audited facility in Canada is one of only a handful worldwide capable of meeting the stringent standards required for pharmaceutical cannabis production. MediPharm Labs continues to uphold its pharmaceutical licenses and remains committed to serving researchers and patients with its brew of cannabinoid products. The company continues to watch developments in U.S. cannabis policy, ready to expand its footprint in the American market. The company plans to release its Q2 financial results for the three and six months ended June 30, 2025, before markets open on Thursday, August 14, 2025. MediPharm develops and manufactures pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients and advanced derivative products. MediPharm Labs stock (TSX:LABS) last traded at $0.07. Though up 25.00 per cent since the year began, the stock has also climbed 7.14 per cent since this time last year. Join the discussion: Find out what the Bullboards are saying about MediPharm Labs and check out Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
The Market Online
27 minutes ago
- The Market Online
Rate-Cut Fever Lifts TSX Futures Higher
TSX futures climbed Wednesday, riding the high from yesterday's record close as cooler U.S. inflation stoked bets the Fed will pull the trigger on a September rate cut. Market Numbers (Futures) TSX : Up ( 0.16%) 27,841.89TSXV: Up (0.76%) 793.24DOW: Up (0.28%) 44,682.00NASDAQ: Up (0.24%) 23,995.00 FTSE: Up (0.16%) 9,162.81 In the Headlines: Liberals are cranking up the investor charm offensive—touring the country ahead of a fall economic update, promising 'certainty' to spark billions in long-term projects, from housing to ports. And Air Canada's flight attendants just dropped a 72-hour strike notice—setting a Saturday walkout in motion and leaving market-watchers bracing for chaos in Canada's skies. Currencies Update: (Futures) The Canadian dollar nudged higher by 0.10% against the greenback to USD72.75, slipped 0.24% versus the euro, while Bitcoin ripped 1.73% to hover at CDN$165,703.08 Commodities: (Futures) Natural Gas: Up (0.43%), 2.82WTI: Down (0.40%), 62.91Gold: Up (0.30%), 3,356.48 Copper: Up (0.07%) 6.06 To stay up-to-date on all of your market news head to Join the discussion: Find out what everybody's saying check out the rest of Stockhouse's stock forums and message boards. The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here
Cision Canada
an hour ago
- Cision Canada
GR Silver Closes Bought Deal Offering with Full Exercise of Over-Allotment Option for Gross Proceeds of $13.8 Million
VANCOUVER, BC, Aug. 13, 2025 /CNW/ - GR Silver Mining Ltd. (" GR Silver Mining" or the " Company") (TSXV: GRSL) (FRANKFURT: GPE) is pleased to announce that it has completed its previously announced (see news release dated July 28, 2025) underwritten private placement offering (the " Offering") issuing 69,000,000 units of the Company (the " Units") at a price of $0.20 per Unit (the " Issue Price"), for aggregate gross proceeds of $13,800,000, including 9,000,000 Units ($1,800,000) sold pursuant to the full exercise of the over-allotment option granted to Research Capital Corporation (the " Underwriter"), the sole underwriter and sole bookrunner, pursuant to the Underwriting Agreement (defined below). Each Unit was comprised of one common share of the Company (a " Common Share") and one-half of one Common Share purchase warrant of the Company (each whole warrant, a " Warrant"). Each Warrant entitles the holder thereof to purchase one Common Share at an exercise price of $0.28 per Common Share at any time until August 13, 2028. The Company intends to use the net proceeds from the Offering for advancement of its Plomosas Silver Project in Mexico, working capital and general corporate purposes. "With the closing of this financing and the full exercise of the over-allotment option, the Company has strengthened its liquidity position," said Marcio Fonseca, President & CEO. "This capital gives us the ability to unlock the value of our Plomosas Project, by advancing the step-out resource expansion drilling program at the San Marcial Area focused on high-grade silver mineralization, and continuing the Bulk Sampling Test Mining ("BSTM") activities at the historic Plomosas Underground Mine. Both activities at the Plomosas Project aim to deliver long-term value for all shareholders , with potential resource expansion and advancing more detailed studies at the past producer underground mine. We thank our investors for their continued confidence and support." The Units were issued pursuant to Part 5A of National Instrument 45-106 – Prospectus Exemptions, as amended by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemptions, to purchasers resident in Canada (other than the province of Québec) and in other qualifying jurisdictions outside of Canada on a private placement basis pursuant to relevant prospectus or registration exemptions in accordance with applicable laws, and are not subject to a statutory hold period pursuant to applicable Canadian securities laws. The Offering remains subject to the final approval of the TSX Venture Exchange. The Company entered into an underwriting agreement (the " Underwriting Agreement") dated August 13, 2025, with the Underwriter, pursuant to which the Company (i) paid the Underwriter a cash commission of $828,000, and (ii) issued an aggregate of 4,140,000 non-transferable broker warrants (the " Broker Warrants"). Each Broker Warrant entitles the holder to purchase one Unit at an exercise price equal to the Offering Price at any time until August 13, 2028. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended, or any U.S. state securities laws, and such securities may not be offered or sold to, or for the account or benefit of, persons in the United States or U.S. persons absent registration under the U.S. Securities Act and all applicable U.S. state securities laws or compliance with the requirements of an exemption therefrom. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. About GR Silver Mining Ltd. GR Silver Mining is a Canadian-based, Mexico-focused mineral exploration company engaged in cost-effective silver-gold resource expansion on its 100%-owned assets, located on the eastern edge of the Rosario Mining District, in the southeast of Sinaloa State, Mexico. GR Silver Mining controls 100% of the Plomosas Project, including the former Plomosas underground mine and wide, high-grade silver mineralized zones at the San Marcial Area. Recent discoveries in the 78 km² of highly prospective, advanced-stage exploration concessions position the Company well for resource expansion at the Plomosas Project. GR Silver Mining Ltd. Márcio Fonseca, President & CEO CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION This news release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts are forward-looking statements. Such forward-looking statements and forward-looking information specifically include, but are not limited to, statements that relate to the use of proceeds of the Offering and the timely receipt of all necessary approvals, including final approval of the TSX Venture Exchange. Such forward ‑ looking statements or information are based on a number of assumptions, which may prove to be incorrect. Assumptions have been made regarding, among other things: conditions in general economic and financial markets; accuracy of assay results; geological interpretations from drilling results, timing and amount of capital expenditures; performance of available laboratory and other related services; future operating costs; and the historical basis for current estimates of potential quantities and grades of target zones. The actual results could differ materially from those anticipated in these forward ‑ looking statements as a result of risk factors, including the timing and content of work programs; results of exploration activities and development of mineral properties; the interpretation and uncertainties of drilling results and other geological data; receipt, maintenance and security of permits and mineral property titles; environmental and other regulatory risks; project costs overruns or unanticipated costs and expenses; availability of funds; failure to delineate potential quantities and grades of the target zones based on historical data; and general market and industry conditions. Forward-looking statements are based on the expectations and opinions of the Company's management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. The Company undertakes no obligation to update or revise any forward-looking statements included in this news release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE GR Silver Mining Ltd.
